enstrom's Macroglobulinemia:
Preliminary Results" demonstrated single agent activity of
perifosine with 36% of patients having a PR or MR. Dr. Irene
Ghobrial of the Dana-Farber Cancer Institute, who presented the
poster, stated, "We are excited at the efficacy and safety results
with perifosine in a patient population for which there is no FDA
approved therapy. We look forward to reporting updated results at
future meetings."
I. Craig Henderson, MD, President of Keryx Biopharmaceuticals,
commented "We are very enthusiastic about the potential of
perifosine in the treatment of multiple myeloma and Waldenstrom's
macroglobulinemia and the prospects of using perifosine to improve
upon the current care for these patients."
In addition to the clinical posters, three pre-clinical posters
were presented, as follows:
Perifosine, an Oral Bioactive Novel Akt Inhibitor, Induces In Vitro and
In Vivo Anti-tumor Activity in Waldenstrom's Macroglobulinemia
Lead Investigator: Xavier Leleu, MD, Dana-Farber Cancer Institute,
Boston, MA
The Combination of Perifosine with Bortezomib and Rituximab Provides
Synergistic Anti-tumor Activity in Waldenstrom's Macroglobulinemia
Lead Investigator: Xavier Leleu, MD, Dana-Farber Cancer Institute,
Boston, MA
Combination of the AKT Inhibitor Perifosine with the HSP90 Inhibitor 17-
(Dimethylaminoethylamino)-17-Demethoxygeldanamycin (17-DMAG) Has
Synergistic Activity in tumor cell and its microenvironment in Multiple
Myeloma (MM)
Lead Investigator: Alissa Huston, MD, University of Pittsburgh
Cancer Center
Copies of all posters can be obtained from Keryx Biopharmaceuticals, Inc.
KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna
Zentaris, Inc. in the United States, Canada and Mexico.
ABOUT KRX-0401 (Perifosine)
KRX-0401 (perifosine) is a novel, first-in-class, oral
anticancer agent that modulat
'"/>
Page: 1 2 3 4 5 6 7 Related medicine technology :1.
Keryx Biopharmaceuticals, Inc. Announces Poster Presentations
Highlighting Mechanism of Action and Clinical Activity of
Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American
Diabetes Association 67th Scientific Sessions in Chicago, Illinois2.
AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results
for Anti-Cancer Compound Perifosine at ASCO Meeting3.
Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial4.
Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis5.
Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis6.
YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial7.
BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine8.
Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis9.
Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone10.
AVI BioPharma Partner Cook Medical Announces Completion of Patient
Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of
Cardiovascular Disease11.
Protox Announces Positive Clinical Data from Prostate Cancer Study